sibutramine has been researched along with Complications of Diabetes Mellitus in 7 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
| Excerpt | Relevance | Reference |
|---|---|---|
| " We studied the response of weight loss therapy with sibutramine and lifestyle change on levels of total bilirubin in an overweight or obese, cardiovascular high-risk population." | 9.14 | Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. ( Andersson, C; Brendorp, B; Caterson, ID; Coutinho, W; Finer, N; Fosbøl, EL; James, WP; Køber, L; Rode, RA; Sharma, AM; Torp-Pedersen, C; Van Gaal, L; Weeke, P, 2009) |
| " We studied the response of weight loss therapy with sibutramine and lifestyle change on levels of total bilirubin in an overweight or obese, cardiovascular high-risk population." | 5.14 | Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. ( Andersson, C; Brendorp, B; Caterson, ID; Coutinho, W; Finer, N; Fosbøl, EL; James, WP; Køber, L; Rode, RA; Sharma, AM; Torp-Pedersen, C; Van Gaal, L; Weeke, P, 2009) |
| "The mean weight loss was greater in the sibutramine group (-7." | 5.11 | Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. ( Kaukua, JK; Pekkarinen, TA; Rissanen, AM, 2004) |
| "We have re-analysed pooled data from seven randomized, controlled studies of sibutramine-induced weight loss and maintenance in which patients (n = 928; 75% female) had taken sibutramine 10 or 15 mg continuously for 12 months, in order to determine the predictors of success in weight loss (defined as loss of at least 5% of initial body weight at Month 12) in both diabetic and non-diabetic patients." | 4.83 | Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. ( Finer, N; Hewkin, AC; Renz, CL; Ryan, DH, 2006) |
| "Obesity is a major risk factor for the development of type 2 diabetes and is an important obstacle to the management of this disease." | 2.40 | Obesity and type 2 diabetes: a conflict of interests? ( Williams, G, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, C | 1 |
| Weeke, P | 1 |
| Fosbøl, EL | 1 |
| Brendorp, B | 1 |
| Køber, L | 1 |
| Coutinho, W | 1 |
| Sharma, AM | 1 |
| Van Gaal, L | 1 |
| Finer, N | 2 |
| James, WP | 1 |
| Caterson, ID | 1 |
| Rode, RA | 1 |
| Torp-Pedersen, C | 1 |
| Saraç, S | 1 |
| Saraç, F | 1 |
| Hauner, H | 1 |
| Kaukua, JK | 1 |
| Pekkarinen, TA | 1 |
| Rissanen, AM | 1 |
| Redmon, JB | 1 |
| Reck, KP | 1 |
| Raatz, SK | 1 |
| Swanson, JE | 1 |
| Kwong, CA | 1 |
| Ji, H | 1 |
| Thomas, W | 1 |
| Bantle, JP | 1 |
| Ryan, DH | 1 |
| Renz, CL | 1 |
| Hewkin, AC | 1 |
| Williams, G | 1 |
2 reviews available for sibutramine and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Diabetes | 2006 |
Obesity and type 2 diabetes: a conflict of interests?
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Complications; Diabetes Mellitus; | 1999 |
4 trials available for sibutramine and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
Topics: Aged; Appetite Depressants; Bilirubin; Biomarkers; Cardiovascular Diseases; Confounding Factors, Epi | 2009 |
Cardiac valve evaluation and adipokine levels in obese women treated with sibutramine.
Topics: Adipokines; Adiponectin; Adult; Appetite Depressants; C-Reactive Protein; Cyclobutanes; Diabetes Com | 2010 |
Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.
Topics: Adult; Aged; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Complications; Diabetes Mel | 2004 |
Two-year outcome of a combination of weight loss therapies for type 2 diabetes.
Topics: Appetite Depressants; Body Mass Index; Body Weight; Combined Modality Therapy; Cyclobutanes; Diabete | 2005 |
1 other study available for sibutramine and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
[A drug help in reducing? Risk profile decides whether and how].
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Cyclobutanes; Diab | 2003 |